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Graft survival rates from deceased donors aged
35 years or less among all primary pediatric kidney
transplant recipients in the United States between
1996 and 2004 were retrospectively examined to de-
termine the effect of HLA-DR mismatches on graft
survival. Zero HLA-DR-mismatched kidneys had sta-
tistically comparable 5-year graft survival (71%), to 1-
DR-mismatched kidneys (69%) and 2-DR-mismatched
kidneys (71%). When compared to donors less than
35 years of age, the relative rate of allograft failure was
1.32 (p = 0.0326) for donor age greater than or equal
to age 35. There was no statistical increase in the odds
of developing a panel-reactive antibody (PRA) greater
than 30% at the time of second waitlisting, based upon
the degree of HLA-A, -B or -DR mismatch of the first
transplant, nor was there a ‘dose effect’ when more
HLA antigens were mismatched between the donor
and recipient. Therefore, pediatric transplant programs
should utilize the recently implemented Organ Pro-
curement and Transplantation Network’s (OPTN) al-
location policy, which prioritizes pediatric recipients
to receive kidneys from deceased donors less than
35 years of age, and should not turn down such
kidney offers to wait for a better HLA-DR-matched
kidney.
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Introduction
Renal transplantation is the optimal treatment for nearly
every child with end-stage renal disease. Between 1996
and 2005, children accounted for only 1.5% or less of re-
nal transplant candidates placed yearly on the Organ Pro-
curement and Transplantation Network’s (OPTN) waiting
list (1). The OPTN’s kidney allocation policies have evolved
over many years. The initial goal was to improve renal
allograft survival by promoting histocompatibility match-
ing between the donor and recipient. However, growing
demand for deceased donor organs caused increases in
waiting time that adversely effected growth, physical and
psychological development and education in children. In
November 1998, the OPTN kidney allocation algorithm was
modified to provide children with new allocation priority
(4 points for those under age 11, and 3 for those aged
11–17, and then local allocation priority to children aged 0–
5, 6–10 and 11–17 years who were not transplanted within
6, 12 or 18 months, respectively). Despite these policies
intended to preferentially distribute deceased donor kid-
neys to children, the median waiting time to transplanta-
tion for pediatric candidates aged 11–17 years increased
between 1995 and 2004 from 276 to 450 days (2). This ob-
servation stimulated a critical review of national deceased
donor organ allocation policies by the OPTN’s Pediatric,
Minority Affairs, and Kidney and Pancreas Transplant Com-
mittees, and led to the implementation of a new OPTN pol-
icy in November 2005, Policy 3.5.11.5.1. This new policy
requires that mismatched kidneys from deceased donors
less than 35 years of age, and allocated within the recover-
ing donor service area for kidney-alone transplantation, be
offered first to kidney transplant candidates who are less
than 18 years of age. This local allocation priority occurs
irrespective of the number of points assigned to the pedi-
atric candidate relative to other waitlisted candidates who
are 18 years of age or older.
The current policy is complex and attempts to bal-
ance both opportunity for transplantation (equity) and
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to optimize renal allograft survival (utility) (3). Deceased
donor kidneys with a blood type compatible zero HLA
antigen-mismatch are still allocated first to pediatric re-
cipients by local, and then by regional, and finally national
priority. Donor and recipient matching at the HLA-A and
HLA-B locus was excluded nationally for both adults and
children from the kidney allocation algorithm, since the sur-
vival benefit from such similarity was found to be small and
to contribute significantly to inequalities in waiting time by
race/ethnicity (4).
The intention of this policy is for pediatric candidates to
undergo kidney transplantation soon after being placed on
the waiting list, avoiding those complications of end-stage
renal disease that are unique to the pediatric population.
These include, but are not limited to, impaired growth and
development and disruption in education (2).
However, critics of this new policy have reasoned that chil-
dren who undergo kidney transplantation soon after being
listed will be less likely to receive kidneys that are well-
matched for HLA. In adults, HLA-DR matching provides a
statistically significant but small clinical benefit in allograft
survival (4). Opponents argue that as a consequence of this
change in allocation policy, pediatric patients will receive
more grafts from poorly HLA-DR-matched donors, wors-
ening the risks of rejection and allograft failure. Addition-
ally, pediatric patients who experience graft loss because
of rejection would subsequently be at risk of developing
anti-HLA antibodies, potentially reducing their access to
repeat transplantation.
There are currently no comprehensive studies to address
these concerns in children. Yet, such a study is necessary
to more completely evaluate the benefits and potential
downsides to the expanded access policy in pediatric trans-
plantation. In an attempt to study these questions, we per-
formed the following analyses of data from the OPTN and
Scientific Registry of Transplant Recipients (SRTR) data-
bases to examine the allograft survival and sensitization
rates of HLA-DR matching in children undergoing deceased
donor kidney transplantation.
Methods
As reported to the OPTN, between January 1, 1996, and
December 31, 2004, 2292 pediatric patients aged 0 to
17 years received a first deceased donor kidney-only trans-
plant. Among these, 1585 (69%) received kidneys from
deceased donors who were 35 years of age or younger.
Adult recipients aged 18–45 (n = 9535) who received a
first deceased donor kidney transplant from a donor aged
35 or younger during the same period were examined
for comparison. Zero HLA antigen-mismatched kidneys
and multiorgan and previous organ transplant recipients
were excluded from analysis (except in Table 1, where
zero mismatched transplants are listed for comparison of
Table 1: A comparison of primary HLA-A, -B, -DR and HLA-DR-
matched kidney transplants to pediatric or young adult recipients
of deceased donors aged 35 or younger
HLA mismatches
0 ABDR 0 DR1
Ages n % n % Total
<5 6 2.1 31 11.2 276
6–10 15 4.5 31 9.6 322
11–17 42 4.1 139 14.1 987
18–45 1557 14.0 2174 22.8 9535
1Excluding 0 HLA-ABDR mismatched grafts.
their frequencies). Log-rank testing was used to compare
the Kaplan–Meier graft survival curves of HLA-DR-antigen-
matched and HLA-DR-antigen-mismatched kidneys in this
pediatric population. Waiting time was defined as the num-
ber of days between the date the patient was added to the
waiting list and the transplant date for the analyses shown
in Figure 5.
In separate analyses of the SRTR database, pediatric re-
cipients aged 0 to 17 who received their first deceased
donor kidney-only transplant between January 11, 1995
and December 31, 2000 were analyzed using a Cox re-
gression model. The relative rate of graft failure was cal-
culated as the time from transplantation until graft failure
or death, censoring at the earliest of last known follow-up
date, or December 31, 2005. The model included indica-
tors for donor age groups (0–10, 11–17, 18–34, 35–49,
>50). The model was adjusted for recipient sex, recipient
race, recipient body mass index (BMI), year transplanted,
panel-reactive antibody (PRA), recipient ABO blood type,
diagnosis group, time on dialysis, donor sex, donor race,
cold ischemic time, donor cause of death, number of HLA
mismatches, number of pretransplant transfusions, double
kidney transplant and donor history of diabetes or hyper-
tension.
An additional model was constructed using a logistic re-
gression to determine the odds of sensitization following
first graft failure among pediatric patients (measured PRA
as reported to the OPTN at the time of second waitlisting),
based on HLA mismatches with the first transplant donor.
This model was adjusted for PRA at time of first transplant,
length of first transplant survival, time since failure of the
first transplant, and the recipient’s race/ethnicity, sex, age,
blood type, previous transfusions and year of transplant.
Results
The distribution of HLA-DR-matched grafts according to re-
cipient ages is shown in Table 1 for the unadjusted compar-
isons. During the 8-year period from 1996 to 2004, very few
pediatric transplant recipients received zero HLA-A,-B,-DR
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Figure 1: Actuarial 5-year graft survival rates among all pedi-
atric recipients by number of HLA-DR mismatches. The p-value
is reported as well as the total number of recipients in each group
(n). This analysis was of pediatric recipients who received their
first kidney transplant from deceased donors 35 years of age or
younger.
(range 2.1–4.5% depending on age and number of trans-
plants) or zero HLA-DR (range 9.6–14.1%)-mismatched
transplants. In contrast, 14.0% and 22.8% of adult recipi-
ents between the ages of 18 and 45 years received zero
HLA-A,-B,-DR or zero HLA-DR-mismatched transplants,
respectively.
Compared to 1-DR-mismatched or 2-DR-mismatched kid-
neys, zero HLA-DR-mismatched matches produced no sta-
tistically significant difference in the 5-year pediatric allo-
graft survival rates (Figure 1). After 5 years, 71% of the
zero- and 2-DR-mismatched grafts survived compared with
69% of those with one HLA-DR mismatch (p = 0.897).
Furthermore, among the subpopulations of pediatric re-
Figure 2: Actuarial 5-year graft survival rates among recipi-
ents under age 5 by the number of HLA-DR mismatches. The
p-value is reported as well as the total number of recipients in
each group (n). This analysis was of pediatric recipients 5 years
old or younger who received their first kidney transplant from a
deceased donor 35 years of age or younger.
Figure 3: Actuarial 5-year graft survival rates among pediatric
recipients aged 6–10 by the number of HLA-DR mismatches.
The p-value is reported as well as the total number of recipients in
each group (n). This analysis was of pediatric recipients 6–10 years
old who received their first kidney transplant from a deceased
donor 35 years of age or younger.
cipients aged 0–5, 6–10 and 11–17 years, there was no
apparent benefit of HLA-DR matching (Figures 2–4).
The analysis of waiting time for pediatric recipients trans-
planted in each DR-match category shown in Figure 5 sug-
gests that within the constraints of the allocation system
during the study period, waiting longer for a kidney did
not result in better-matched transplants. In fact, HLA-DR-
matched kidneys tended to be transplanted into pediatric
recipients sooner than DR-mismatched kidneys.
As shown in Figure 6, the overall 5-year graft survival rate
for adult recipients aged 19–45 years was superior to that
for adolescent recipients (75% vs. 65%, p < 0.001), but
Figure 4: Actuarial 5-year graft survival rates among adoles-
cent recipients by the number of HLA-DR mismatches. The p-
value is reported as well as the total number of recipients in each
group (n). This analysis was of pediatric recipients 11–17 years old
who received their first kidney transplant from a deceased donor
35 years of age or younger.
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Figure 5: Time to transplant for pediatric recipients by level
of HLA-DR mismatch, the time to transplant was defined as
the difference between the transplant date and the date the
patient was added to the waiting list. The total number of
recipients is reported in each group (n). This analysis was of re-
nal transplant recipients who received their first kidney transplant
from a deceased donor 35 years of age or younger and excludes
recipients of zero HLA-A, -B and -DR-mismatched transplants.
not significantly different from that observed of recipients
aged 0–5 years (80%) or 6–10 years (77%).
In the adjusted model, 1470 pediatric patients received
kidney transplants during the study period. Of these, 933
(63.5%) were in the 10- to 17-year-old age range. There
were 365 graft failures and 31 deaths during the study
period. The mean age of the donors was 26.4 and the
age range was from <1 to 73 years. Eighty-five percent
of donors were between 6 years and 48 years, and 65%
were between 16 years and 48 years. When compared
to donors less than 35 years of age, the relative rate of
allograft failure was 1.32 (p = 0.033) for donor age ≥35
(Figure 7).
Figure 6: The 5-year graft survival rates of adult, adolescent






































Figure 7: Relative risk of graft failure for pediatric first trans-
plant recipients according to donor age group. Adjusted for re-
cipient sex, recipient race, recipient BMI, year transplanted, PRA,
recipient ABO blood type, diagnosis group, time on dialysis, donor
sex, donor race, cold ischemic time, donor cause of death, number
of HLA mismatches, number of pretransplant transfusions, double
kidney transplant and donor history of diabetes or hypertension.
Also available for analysis were 313 second waitlisted can-
didates whose PRA at the time of first transplant was less
than 30%. This number excluded patients whose PRA at
first transplant or second waitlisting were not available.
Only seven patients received a zero ABDR mismatched
kidney at first transplant, and they were included in this
analysis. There was no statistical increase in the odds of
developing a PRA greater than 30% at the time of second
waitlisting, based upon the degree of HLA-A, -B or -DR
mismatch of the first transplant (Table 2), nor was there a
‘dose effect’ when more HLA antigens were mismatched
between the donor and recipient.
Discussion
Living donor kidney transplants have superior allograft sur-
vival compared with even the best-matched deceased
donor kidney transplants (5). However, controversy re-
mains regarding the importance of HLA matching among
renal allograft recipients who do not have a suitable living
Table 2: The odds of sensitization (PRA >30%) at second wait-
listing, based upon HLA mismatch of the first transplant
N OR p-Value
Mismatch at first Tx
0 A 32 1 Ref
1 A 138 0.72 0.56
2 A 143 1.02 0.972
0 B 19 1 Ref
1 B 105 3.66 0.129
2 B 189 2.28 0.329
0 DR 72 1 Ref
1 DR 158 0.4 0.021
2 DR 83 0.56 0.202
Tx = transplant; Ref = reference.
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donor. Adult recipients of zero HLA-A, -B, -DR-mismatched
deceased donor kidney transplants have a 3–4% improve-
ment in 5-year graft survival compared to those with any
HLA mismatch. Adult recipients with a zero HLA-DR mis-
match have significantly fewer rejection episodes in the
first year (6) and, as a result, may receive less cumula-
tive immunosuppression during the life of their transplant.
Similarly, adult patients who experience graft failure are
less likely to become broadly sensitized if the allograft had
fewer mismatched HLA antigens (7).
These considerations may be important for pediatric renal
transplant recipients, who may require repeat transplan-
tation at some time during their life. Thus, living donor
and HLA-matched transplants for pediatric patients would
seem to be the best options for transplantation when fea-
sible. Unfortunately, the extensive polymorphisms of the
HLA antigen system make finding well-matched deceased
donor kidneys difficult, even among very large numbers of
potential donors and waitlisted candidates. When we con-
sider the added limitations of smaller local donor pools and
populations of waitlisted pediatric candidates and further
restrictions imposed by the requirement for ABO compat-
ibility and technical requirements for pediatric transplanta-
tion, the small numbers of pediatric recipients of HLA-A,
-B, -DR and HLA-DR-matched grafts shown in Table 1 are
easily understood. More pediatric patients might receive
HLA-matched grafts if they waited longer, but waiting re-
sults in prolonged dialysis exposure that is associated with
impaired growth and social and physical development, and
increased risk of dialysis access failure.
The literature concerning the beneficial effect of DR match-
ing for pediatric recipients has been inconclusive. A single-
center study by Barocci and associates (8) suggested that
matching of HLA-DR antigens leads to improved graft sur-
vival, while another single-center study by El-Husseini et al.
(9) reported that HLA-DR matching had no significant im-
pact on graft survival. A very large multivariate analysis
of 8442 pediatric kidney transplant recipients reported to
the OPTN/UNOS database between October 1987 and De-
cember 1998 also failed to show a statistically significant
1- and 5-year graft survival benefit with HLA-A, -B or -DR
matching (10).
The three analyses reported here of OPTN and SRTR data
were prepared separately and used for OPTN policy de-
velopment. The analysis is of pediatric patients during a
period when the organ allocation policies for pediatric re-
cipients were stable. They are reported here to provide
data to the transplant community explaining the rationale
for the change in pediatric organ allocation policy so that
patients can be informed of the risks and benefits relating
to acceptance of donor organs. Our retrospective analysis
of more recent nationwide cohorts of pediatric recipients
of primary deceased donor kidney transplants confirms
that pediatric candidates for kidney transplantation are not
penalized in terms of allograft survival or subsequent sen-
sitization by accepting a mismatched kidney from a de-
ceased donor. We were unable to demonstrate allograft
survival improvement among pediatric recipients who re-
ceived better HLA-DR-matched kidney transplants during
the 10-year study period. This was true regardless of the
pediatric age group studied.
Of course, even these larger studies are hampered by
the paucity of well-matched grafts in the pediatric popu-
lation. Thus, it may be speculative to conclude that closer-
matched grafts would not fare better than poorly matched
grafts in the long term. However, it is clear that under
the previous allocation system, pediatric patients rarely
received well-matched grafts. The notion that it benefits
pediatric kidney transplant candidates to remain on the
waiting list in order to receive a better HLA-matched kid-
ney allograft is also refuted by the results in Figure 5. The
lack of a clear survival benefit for pediatric recipients of
HLA-DR-matched kidneys, and the observation that HLA-
DR-matched transplants tend to be performed at least as
quickly as mismatched transplants, suggests that there is
no advantage for pediatric patients to remain on the wait-
ing list in the hope of obtaining a better HLA-DR-matched
transplant.
The new pediatric deceased donor kidney allocation policy
attempts to improve long-term patient survival by minimiz-
ing time spent on dialysis. The policy also has the potential
to decrease the exposure to HLA antigens due to blood
transfusion and subsequent sensitization. This policy may
also facilitate deceased donor transplantation before the
initiation of dialysis. Deceased donors less than 35 years of
age are more likely to have died as a result of trauma rather
than from consequences of vascular disease, another sig-
nificant determinant of improved graft survival (10).
Some concerns have been raised regarding the impact on
living donation of giving near-absolute local allocation pri-
ority to pediatric patients for donors less than 35 years
of age. It has been argued that providing very rapid de-
ceased donor kidney transplantation to pediatric recipients
may reduce the incentive for their loved ones to donate.
It is important to emphasize to patients and their families
the significant benefits of living donor compared to de-
ceased donor renal transplantation. Nevertheless, if there
were a decline in initial live donation as a result of this
policy change, family members who might have donated
initially would still be available should retransplantation be
necessary for that individual in the future.
Another concern that has been raised is that prioritizing
‘ideal’ kidneys to the pediatric population may severely dis-
advantage adult candidates and transplant centers lacking
pediatric programs. However, because the proportion of
pediatric candidates on the waiting list is stable and nomi-
nal (approximately 700–800 per year) in comparison to the
adult population, the new pediatric priority policy will only
marginally shift the mean age of the donor, and will not
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markedly decrease the volume of kidneys transplanted into
the adult population (10).
The adolescent recipient population might theoretically
pose a problem for this new policy. This population has de-
creased 5-year graft survival when compared to 19–45 year
olds. New trials to carefully monitor immunosuppressive
pharmacology and adherence to treatment will hopefully
improve the outcomes. Allotment of ‘ideal’ kidneys to
the adult population rather than adolescents might have
a greater societal benefit (1,10–13). Ultimately, however,
it is up to the individual transplantation teams to ensure
that each pediatric recipient is a suitable candidate to re-
ceive this valuable organ. This includes appropriate social
and financial support. Numerous efforts are underway to
improve medication compliance and physician follow-up in
this higher risk group.
The strongest modifiable risk factor for renal transplant out-
comes is waiting time on dialysis (14). In fact, the best out-
comes occur in recipients who preemptively receive a kid-
ney transplant before dialysis becomes necessary (15,16).
Based on the current data, pediatric transplant recipients
with HLA-DR-mismatched kidneys enjoy essentially the
same graft survival as their HLA-DR-matched counterparts.
Therefore, transplant centers should not hesitate to accept
HLA-DR-mismatched kidneys from deceased donors less
than 35 years of age in order to expedite the transplan-
tation process for the majority of nonsensitized pediatric
candidates for first transplants.
Conclusion
OPTN policy now prioritizes kidneys from deceased donors
less than 35 years of age to pediatric candidates. This pol-
icy should improve the allocation of this scarce resource
while minimizing the morbidity associated with prolonged
exposure to dialysis for children. There is no demonstra-
ble allograft survival benefit for HLA-DR-matched pediatric
kidney transplantation. Therefore, pediatric transplant pro-
grams should not hesitate to accept HLA-DR-mismatched
kidneys from deceased donors less than 35 years of age.
It is expected that this policy will lead to shorter pedi-
atric waiting time. As the pediatric waiting list begins to
shorten, it will be important that pediatric transplant pro-
grams optimize their patients prior to listing for deceased
donor transplantation. The long-term effects of this change
in allocation policy will need to be monitored to ensure the
best outcomes for children with end-stage renal disease.
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